Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Mesía R[au]:

Human papillomavirus-related oropharyngeal cancer. Taberna M et al. Ann Oncol. (2017)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Taberna M et al. Front Oncol. (2019)

p16, HPV, and Cetuximab: What Is the Evidence? Bonner JA et al. Oncologist. (2017)

Search results

Items: 1 to 50 of 86

1.

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions.

Guigay J, Tahara M, Licitra L, Keilholz U, Friesland S, Witzler P, Mesía R.

Front Oncol. 2019 Aug 21;9:668. doi: 10.3389/fonc.2019.00668. eCollection 2019. Review.

2.

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Taberna M, Oliva M, Mesía R.

Front Oncol. 2019 May 20;9:383. doi: 10.3389/fonc.2019.00383. eCollection 2019. Review.

3.

Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population.

Fernández-Mateos J, Seijas-Tamayo R, Adansa Klain JC, Pastor Borgoñón M, Pérez-Ruiz E, Mesía R, Del Barco E, Salvador Coloma C, Rueda Dominguez A, Caballero Daroqui J, Fernández Ruiz E, Ocana A, González-Sarmiento R, Cruz-Hernández JJ.

Cancers (Basel). 2019 Apr 7;11(4). pii: E493. doi: 10.3390/cancers11040493.

4.

The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer.

Castet F, Brenes J, Taberna M, Mesía R.

Curr Opin Oncol. 2019 May;31(3):160-168. doi: 10.1097/CCO.0000000000000530.

PMID:
30844888
5.

The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients.

Taberna M, Torres M, Alejo M, Mena M, Tous S, Marquez S, Pavón MA, León X, García J, Guix M, Hijano R, Bonfill T, Aguilà A, Lozano A, Mesía R, Alemany L, Bravo IG.

Front Oncol. 2018 Dec 11;8:589. doi: 10.3389/fonc.2018.00589. eCollection 2018.

6.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

7.

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.

Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, Siu LL.

Ann Oncol. 2019 Jan 1;30(1):57-67. doi: 10.1093/annonc/mdy507.

8.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.

PMID:
30383184
9.

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.

Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R.

Int J Mol Sci. 2018 Oct 19;19(10). pii: E3249. doi: 10.3390/ijms19103249. Review.

10.

Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era.

Marín M, Gudiol C, Castet F, Oliva M, Peiró I, Royo-Cebrecos C, Carratalà J, Mesia R.

Clin Transl Oncol. 2019 Feb;21(2):187-196. doi: 10.1007/s12094-018-1905-5. Epub 2018 Jun 11.

PMID:
29948973
11.

HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival.

Taberna M, Mena M, Tous S, Pavón MA, Oliva M, León X, Garcia J, Guix M, Hijano R, Bonfill T, Aguilà A, Alemany L, Mesía R.

PLoS One. 2018 Apr 17;13(4):e0194107. doi: 10.1371/journal.pone.0194107. eCollection 2018.

12.

Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients.

Mena M, Taberna M, Tous S, Marquez S, Clavero O, Quiros B, Lloveras B, Alejo M, Leon X, Quer M, Bagué S, Mesia R, Nogués J, Gomà M, Aguila A, Bonfill T, Blazquez C, Guix M, Hijano R, Torres M, Holzinger D, Pawlita M, Pavon MA, Bravo IG, de Sanjosé S, Bosch FX, Alemany L.

Oral Oncol. 2018 Mar;78:137-144. doi: 10.1016/j.oraloncology.2018.01.010. Epub 2018 Feb 20.

PMID:
29496041
13.

Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.

Soulières D, Licitra L, Mesía R, Remenár É, Li SH, Karpenko A, Chol M, Wang YA, Solovieff N, Bourdeau L, Sellami D, Faivre S.

Clin Cancer Res. 2018 Jun 1;24(11):2505-2516. doi: 10.1158/1078-0432.CCR-17-2644. Epub 2018 Feb 28.

14.

SEOM clinical guideline in nasopharynx cancer (2017).

Pastor M, Lopez Pousa A, Del Barco E, Perez Segura P, Astorga BG, Castelo B, Bonfill T, Martinez Trufero J, Grau JJ, Mesia R.

Clin Transl Oncol. 2018 Jan;20(1):84-88. doi: 10.1007/s12094-017-1777-0. Epub 2017 Nov 2.

15.

Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma.

Fernández-Mateos J, Seijas-Tamayo R, Klain JCA, Borgoñón MP, Pérez-Ruiz E, Mesía R, Del Barco E, Coloma CS, Dominguez AR, Daroqui JC, Fernández Ruiz E, Cruz-Hernández JJ, González-Sarmiento R.

Sci Rep. 2017 Jul 31;7(1):6887. doi: 10.1038/s41598-017-07270-0.

16.

Nutritional changes in patients with locally advanced head and neck cancer during treatment.

Arribas L, Hurtós L, Taberna M, Peiró I, Vilajosana E, Lozano A, Vazquez S, Mesia R, Virgili N.

Oral Oncol. 2017 Aug;71:67-74. doi: 10.1016/j.oraloncology.2017.06.003. Epub 2017 Jun 10.

PMID:
28688694
17.

Human papillomavirus-related oropharyngeal cancer.

Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R.

Ann Oncol. 2017 Oct 1;28(10):2386-2398. doi: 10.1093/annonc/mdx304. Review.

PMID:
28633362
18.

p16, HPV, and Cetuximab: What Is the Evidence?

Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, Beier F, Schulten J, Vermorken JB.

Oncologist. 2017 Jul;22(7):811-822. doi: 10.1634/theoncologist.2016-0433. Epub 2017 May 18. Review.

19.

HPV-related oropharyngeal carcinoma de-escalation protocols.

Mesía R, Taberna M.

Lancet Oncol. 2017 Jun;18(6):704-705. doi: 10.1016/S1470-2045(17)30250-4. Epub 2017 Apr 20. No abstract available.

PMID:
28434659
20.

Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2).

Rueda A, Giralt J, Mañós M, Lozano A, Sistiaga A, García-Miragall E, Cacicedo J, Esteban F, Scola B, Contreras J, Ruiz A, Carral A, Sanchez-Aniceto G, Pastor M, Herranz JJ, Bernal M, Mesía R.

Oral Oncol. 2017 Jul;70:65-72. doi: 10.1016/j.oraloncology.2017.04.005. Epub 2017 Apr 17. Review.

21.

Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).

Mañós M, Giralt J, Rueda A, Cabrera J, Martinez-Trufero J, Marruecos J, Lopez-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F, Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesía R.

Oral Oncol. 2017 Jul;70:58-64. doi: 10.1016/j.oraloncology.2017.04.004. Epub 2017 Apr 17. Review.

22.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L.

Lancet Oncol. 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. Epub 2017 Jan 26.

PMID:
28131786
23.

Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.

Mesía R, Garcia-Saenz JA, Lozano A, Pastor M, Grau JJ, Martínez-Trufero J, Lambeaz J, Martínez-Galán J, Mel JR, González B, Vázquez S, Mañós M, Taberna M, Cirauqui B, Del Barco E, Casado E, Rubió-Casadevall J, Rodríguez-Jaráiz A, Cruz JJ; Spanish Head And Neck Cancer Cooperative Group (Study TTCC-2007/02).

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):473-480. doi: 10.1016/j.ijrobp.2016.11.016. Epub 2016 Nov 17.

PMID:
28011050
24.

Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.

Fernández-Mateos J, Seijas-Tamayo R, Mesía R, Taberna M, Pastor Borgoñón M, Pérez-Ruiz E, Adansa Klain JC, Vázquez Fernández S, Del Barco Morillo E, Lozano A, González Sarmiento R, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Oral Oncol. 2016 Dec;63:38-43. doi: 10.1016/j.oraloncology.2016.10.006. Epub 2016 Nov 12.

25.

Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.

Del Barco Morillo E, Mesía R, Adansa Klain JC, Vázquez Fernández S, Martínez-Galán J, Pastor Borgoñon M, González-Rivas C, Caballero Daroqui J, Berrocal A, Martínez-Trufero J, Vera R, Cruz-Hernández JJ; Spanish Head And Neck Cancer Cooperative Group (TTCC).

Oral Oncol. 2016 Nov;62:54-59. doi: 10.1016/j.oraloncology.2016.09.009. Epub 2016 Oct 8.

PMID:
27865372
26.

Systemic inflammatory responses in patients with type 2 diabetes with chronic periodontitis.

Mesia R, Gholami F, Huang H, Clare-Salzler M, Aukhil I, Wallet SM, Shaddox LM.

BMJ Open Diabetes Res Care. 2016 Sep 8;4(1):e000260. doi: 10.1136/bmjdrc-2016-000260. eCollection 2016.

27.

Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy.

Rovira A, Tornero J, Oliva M, Taberna M, Montal R, Nogues J, Farre A, Lares H, Navarro V, Mari A, Vinals JM, Lozano A, Mesia R, Manos M.

Head Neck. 2017 Jan;39(1):116-121. doi: 10.1002/hed.24549. Epub 2016 Jul 26.

PMID:
27459296
28.

Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer.

Licitra L, Keilholz U, Tahara M, Lin JC, Chomette P, Ceruse P, Harrington K, Mesia R.

Oral Oncol. 2016 Aug;59:73-79. doi: 10.1016/j.oraloncology.2016.06.002. Review.

29.

Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases.

Holguin F, Rubió-Casadevall J, Saigi M, Marruecos J, Taberna M, Tobed M, Maños M, Mesía R.

J Chemother. 2017 Oct;29(5):310-313. doi: 10.1080/1120009X.2016.1187360. Epub 2016 Jul 5.

PMID:
27380218
30.

Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location.

Seijas-Tamayo R, Fernández-Mateos J, Adansa Klain JC, Mesía R, Pastor Borgoñón M, Pérez-Ruiz E, Vázquez Fernández S, Salvador Coloma C, Rueda Domínguez A, Taberna M, Martínez-Trufero J, Bonfill Abella T, Vázquez Estévez S, Pollán M, Del Barco Morillo E, Cruz-Hernández JJ.

Clin Transl Oncol. 2016 Nov;18(11):1114-1122. Epub 2016 Apr 25.

PMID:
27112939
31.

Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma.

Grau JJ, Mesía R, de la Iglesia-Vicente M, Williams ES, Taberna M, Caballero M, Larque AB, de la Oliva J, Cordón-Cardo C, Domingo-Domenech J.

Oncology. 2016;90(5):267-72. doi: 10.1159/000445118. Epub 2016 Apr 15.

PMID:
27077749
32.

Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab.

Montal R, Oliva M, Taberna M, De Avila L, Rovira A, Cos M, Mañós M, Navarro V, Nogués J, Lozano A, Rodríguez L, Vilajosana E, Vázquez S, Mesia R.

Clin Transl Oncol. 2016 Nov;18(11):1140-1146. Epub 2016 Mar 10.

PMID:
26960559
33.

Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck.

Linares J, Rullan A, Taberna M, Vazquez S, Mesia R.

Oral Oncol. 2016 Apr;55:e4. doi: 10.1016/j.oraloncology.2016.02.006. Epub 2016 Feb 28. No abstract available.

PMID:
26924081
34.

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.

Mesía R, Vázquez S, Grau JJ, García-Sáenz JA, Lozano A, García C, Carles J, Irigoyen A, Mañós M, García-Paredes B, del Barco E, Taberna M, Escobar Y, Cruz JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):289-96. doi: 10.1016/j.ijrobp.2015.10.019. Epub 2015 Oct 22.

PMID:
26675064
35.

Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck.

Licitra L, Mesía R, Keilholz U.

Oral Oncol. 2016 Jan;52:18-23. doi: 10.1016/j.oraloncology.2015.10.020. Epub 2015 Nov 11. Review.

PMID:
26578389
36.

Late toxicity after radical treatment for locally advanced head and neck cancer.

Taberna M, Rullan AJ, Hierro C, Navarro V, Vázquez S, Lozano A, Vilajosana E, Maños M, Marí A, Viñals J, Mesía R.

Oral Oncol. 2015 Aug;51(8):795-9. doi: 10.1016/j.oraloncology.2015.05.002. Epub 2015 Jun 4.

PMID:
26051499
37.

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.

Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J.

Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15.

PMID:
25596660
38.

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesía R, Zhang A, Oliner KS, VanderWalde A.

Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15.

PMID:
25596659
39.

Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and Neck.

de Llobet LI, Baro M, Mesia R, Balart J.

Transl Oncol. 2014 Aug;7(4):513-22. doi: 10.1016/j.tranon.2014.02.008. Epub 2014 Mar 5.

40.

The effect of dynamic loading on bacterial colonization of the dental implant fixture-abutment interface: an in vitro study.

Koutouzis T, Mesia R, Calderon N, Wong F, Wallet S.

J Oral Implantol. 2014 Aug;40(4):432-7. doi: 10.1563/AAID-JOI-D-11-00207.

PMID:
25106007
41.

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.

Baro M, de Llobet LI, Figueras A, Skvortsova I, Mesia R, Balart J.

Br J Cancer. 2014 Sep 23;111(7):1310-8. doi: 10.1038/bjc.2014.432. Epub 2014 Jul 31.

42.

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.

Vermorken JB, Psyrri A, Mesía R, Peyrade F, Beier F, de Blas B, Celik I, Licitra L.

Ann Oncol. 2014 Apr;25(4):801-7. doi: 10.1093/annonc/mdt574. Epub 2014 Feb 26.

43.

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM.

Ann Oncol. 2014 Mar;25(3):682-8. doi: 10.1093/annonc/mdu003.

44.

SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013.

Mesía R, Pastor M, Grau JJ, del Barco E; SEOM.

Clin Transl Oncol. 2013 Dec;15(12):1018-24. doi: 10.1007/s12094-013-1096-z. Epub 2013 Aug 27.

PMID:
23982853
45.

SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013.

Mesía R, Pastor M, Grau JJ, del Barco E; SEOM.

Clin Transl Oncol. 2013 Dec;15(12):1025-9. doi: 10.1007/s12094-013-1094-1. Epub 2013 Aug 27.

PMID:
23982852
46.

Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial.

Mesía R, Rueda A, Vera R, Lozano A, Medina JA, Aguiar D, Árias F, Triana G, Carles J, López-López R.

Ann Oncol. 2013 Feb;24(2):448-53. doi: 10.1093/annonc/mds291. Epub 2012 Oct 5.

PMID:
23041591
47.

Development and characterization of an isogenic cell line with a radioresistant phenotype.

de Llobet LI, Baro M, Figueras A, Modolell I, Da Silva MV, Muñoz P, Navarro A, Mesia R, Balart J.

Clin Transl Oncol. 2013 Mar;15(3):189-97. doi: 10.1007/s12094-012-0898-8. Epub 2012 Jul 24.

PMID:
22855182
48.

The Effect of Dynamic Loading on Bacterial Colonization of the Dental Implant Fixture-Abutment Interface: An In-vitro Study.

Koutouzis T, Mesia R, Calderon N, Wong F, Wallet S.

J Oral Implantol. 2012 May 7. [Epub ahead of print]

PMID:
22564184
49.

Epigenetic disruption of cadherin-11 in human cancer metastasis.

Carmona FJ, Villanueva A, Vidal A, Muñoz C, Puertas S, Penin RM, Gomà M, Lujambio A, Piulats JM, Mesía R, Sánchez-Céspedes M, Manós M, Condom E, Eccles SA, Esteller M.

J Pathol. 2012 Oct;228(2):230-40. doi: 10.1002/path.4011. Epub 2012 Jul 26.

50.

Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.

Bernier J, Russi EG, Homey B, Merlano MC, Mesía R, Peyrade F, Budach W.

Ann Oncol. 2011 Oct;22(10):2191-200. doi: 10.1093/annonc/mdr139. Epub 2011 May 23.

PMID:
21606209

Supplemental Content

Support Center